secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001437749-23-024896
Event type: litigation
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Intas Pharmaceuticals files PGR petition challenging Atossa's endoxifen patent
------------------------------------------------------------------------------

- Intas Pharmaceuticals filed a Post-Grant Review petition with USPTO challenging Atossa's U.S. Patent No. 11,572,334.
- Patent covers methods for making and using endoxifen.
- Atossa intends to contest the PGR and believes the patent is valid and enforceable.
- No assurance of prevailing; Intas will be estopped from raising certain arguments in future litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923024896/0001437749-23-024896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923024896/atos20230830_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-024896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer